ET
Therapeutic Areas
Jasper Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Briquilimab (JSP191) | Conditioning for HSCT in Severe Combined Immunodeficiency (SCID) | Phase 1/2 / Pivotal Path |
Leadership Team at Jasper Therapeutics
RM
Ronald Martell
President and Chief Executive Officer
WW
Wen-Kai Weng, M.D., Ph.D.
Chief Medical Officer
AF
Anna French, Ph.D.
Chief Operating Officer
SH
Scott Harris
General Counsel
HB
Heather Behanna, Ph.D.
SVP, Investor Relations & Corporate Communications